A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 438 participants.
Also called NCT07477704
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 438 participants
- Sponsor
- Registry
-
NCT07477704
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07477704. Randomized; no masking; primary purpose treatment. Start 2026-06-17 (actual); primary completion 2026-12-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Acronym
- ASCEND-QW
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07477704- Content hash
52e4b860ddd5ac9da5fd74497e78cfade5f034204de6b3affc2975406834e341